Фармакоэкономические аспекты терапии шизофрении
Рекомендуемое оформление библиографической ссылки:
Алтынбеков К.С. Фармакоэкономические аспекты терапии шизофрении // Российский психиатрический журнал. 2014. №6. С. 51-55.
В статье показан фармакоэкономический аспект терапии шизофрении. Обсуждается вопрос длительной терапии шизофрении в сравнительном аспекте между традиционными нейролептиками и атипичными антипсихотическими препаратами.
1. Воробьев П.А., Авксентьева М.В., Юрьев А.С. и др. Клиникоэкономический анализ (оценка, выбор медицинских технологий и управление качеством медицинской помощи. - М.: Ньюдиамед, 2004. - 404 с. 2. Гурович И.Я., Любов Е.Б. Фармакоэпидемиология и фармакоэкономика в психиатрии. - М.: Медпрактика, 2003. - 264 с. 3. Краснов В.Н., Гурович И.Я., Мосолов С.Н., Шмуклер А.Б. Психиатрическая помощь больным шизофренией: Клиническое руководство. - М.: Медпрактика-М, 2007. - 260 с. 4. Любов Е.Б. Фармакоэкономические исследования в психиатрии // Соц. и клин. психиатрия. - 1999. - Т. 9, № 1. - С. 89-96. 5. Azorin J.-M., Murteira S., Hansen K. et al. Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis // BMC Psychiatry. - 2008. - Vol. 8, N 16. 6. Azorin J.-M., Toumi M., Sloth-Nielsen M. Sertindole is well tolerated and demonstrates efficacy advantages over risperidone in the treatment of moderate to severe schizophrenia // Poster presented at ECNP. Barcelona, 5-9 October 2002. 7. Branford D., Thompson B., Muldoon C. Mortality in three comparative cohorts of patients who received sertindole, risperidone, and olanzapine: a hospital-based retrospective study // Poster presented at ICPE. Edinburgh, 18-21 August 2002. 8. Daniel D.G., Wozniak P.J., Mack R.J. et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia // Psychopharmacol. Bull. - 1998. - Vol. 34. - P. 61-69. 9. Gallhofer B., Jaanson P., Mittoux A. et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidol // Pharmacopsychiatry. - 2007. - Vol. 40. - P. 275-288. 10. Ereshefsky L., Toumi M., Francois C. Association of sertindole with reduction in healthcare resource use by patients with schizophrenia // Poster presented at ICOSR, Colorado Springs, Colorado, 29 March-02 April, 2003. 11. Hale A. Sertindole: a clinical efficacy profile // Psychiatry Clin. Pract. - 2002. - Vol. 6, suppl. 1. - P. S21-S26. 12. Hale A., Azorin J-M., Kasper S. et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial // Int. J. Psychiatry Clin. Pract. - 2000. - Vol. 4. - P. 55-62. 13. Hale A.S. A review of the safety and tolerability of sertindole // Int. Clin. Psychopharmacol. - 1998. - Vol. 13, suppl. 3. - P. S65-S70. 14. Hansen K., Bitter I., Launois R. et al. Pharmacoeconomic positioning of sertindole among antipsychotics in the management of schizophrenia: the Hungarian experience // Poster presented at the 9 th European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Copenhagen, Denmark, 28-31 October, 2006. 15. Hansen K., Launois R., Sapin C. Pharmacoeconomic positioning of sertindole among atypical antipsychotics in the management of schizophrenia in Turkey // Poster presented at the International Health Economic Association (IHEA) Conference, Copenhagen, Denmark, 2007. 16. Hansen K., Sapin C., Toumi M. Sertindole in the treatment of schizophrenia in Poland: a cost analysis // Poster presented at the 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Dublin, Ireland, 20-23 October, 2007. 17. Launois R., Von der Schulenburg M.G., Knapp M. et al. Costeffectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model // Int. J. Psychiatry Clin. Pract. - 1998. - Vol. 2, suppl. 2. - P. S79-S86. 18. Leucht S., Komossa K., Rummel-Kluge C. et al. A meta-analysis of second generation antipsychotics in the treatment of schizophrenia // Am. J. Psychiatry. - 2009. - Vol. 166, N 2. - P. 152-163. 19. Lindstrom E., Eberhard J., Fors M.B. et al. A pharmacoeconomic analysis of schizophrenia management in Sweden // Poster presented at the 14th European Congress of Psychiatry. Nice, France, 4-8 March 2006. 20. Mаhlum E., Hansen K., Sapin C. Pharmacoeconomic positioning of sertindole among antipsychotics in the management of schizophrenia in Norway // Presented at the 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcome Research (ISPOR). Athens, Greece, 8-11 November 2008. 21. Murdoch D., Keating G.M. Sertindole. A review of its use in schizophrenia // CNS Drugs. - 2006. - Vol. 20, N 3. - P. 233-255. 22. Naber D., Lambert M. Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients // Int. J. Psychiatry Clin. Pract. - 1998. - Vol. 2, suppl. 2. - P. S73-S77. 23. Perquin L., Steinert T. Review of the efficacy, tolerability and safety of sertindole in clinical trials // CNS Drugs. - 2004. - Vol. 18, suppl. 2. - P. 19-30. 24. Sapin C., Azorin J.M., Le Lay A. et al. Sertindole reduces health care consumption in schizophrenia: results of a mirror study // Poster presented at the 20 th Int. Conf. on Pharmacoepidemiology & Therapeutic Risk Management. - Bordeaux, France, August 22-25, 2004. 25. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? // Psychiatr. Q. - 2002. - Vol. 73, N 4. - P. 297-311.
DOI: http://dx.doi.org/10.24411/1560-957X-2014-1%25x
Метрики статей
Metrics powered by PLOS ALM